dc.contributor.author |
López-Meseguer, Manuel |
dc.contributor.author |
Quezada, Carlos A. |
dc.contributor.author |
Ramon, Maria A. |
dc.contributor.author |
Lázaro, María |
dc.contributor.author |
Dos, Laura |
dc.contributor.author |
Lara, Antonio |
dc.contributor.author |
López, Raquel |
dc.contributor.author |
Blanco, Isabel |
dc.contributor.author |
Escribano, Pilar |
dc.contributor.author |
Roman, Antonio |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2017 |
dc.identifier |
https://ddd.uab.cat/record/254039 |
dc.identifier |
urn:10.1371/journal.pone.0187811 |
dc.identifier |
urn:oai:ddd.uab.cat:254039 |
dc.identifier |
urn:pmcid:PMC5697851 |
dc.identifier |
urn:pmc-uid:5697851 |
dc.identifier |
urn:pmid:29161284 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5697851 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/11f22490-4562-4a00-8f4d-d54684cdfed2 |
dc.identifier |
urn:scopus_id:85034758725 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
PloS one ; Vol. 12 (november 2017) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.title |
Lung and heart-lung transplantation in pulmonary arterial hypertension |
dc.type |
Article |
dc.description.abstract |
Real use of lung (LT) and heart-lung (HLT) transplantation in pulmonary arterial hypertension (PAH) is unknown. The objectives were to describe the indication of these procedures on PAH treatment in a national cohort of PAH patients, and to analyze the potential improvement of its indication in severe patients. Eligibility for LT/HLT was assessed for each deceased patient. Incident patients from REHAP diagnosed between January 2007 and March 2015 and considered eligible for LT/HLT were grouped as follows: those who finally underwent transplantation (LTP) and those who died (D-Non-LT). Of 1391 patients included in REHAP, 36 (3%) were LTP and 375 (27%) died. Among those who died, 36 (3%) were D-Non-LT. LTP and D-Non-LT were equal in terms of age, gender, and clinical status. Ten percent of those who died were functional class I-II. Patients functional class IV were less likely to undergo LT (8.3% LTP vs. 30.6% D-Non-LT, p = 0.017). Patients with idiopathic and drug/toxin-associated PAH were more likely to undergo LT (44.4% LTP vs. 16.7% D-Non-LT, p = 0.011). The present results show that the use of LT/HLT could double for this indication. Relevant mortality in early functional class reflects the difficulties in establishing the risk of death in PAH. |